Jidong Jia, chief physician, professor and doctoral supervisor, director of The Liver Disease Research Center of Beijing Friendship Hospital, Capital Medical University. He is currently member of the professional committee on Liver Diseases of Chinese Association of Gastroenterology of CMDA , member of the Standing Committee of Chinese Society of Clinical Pharmacy of CMA. He also serves China Foundation of Hepatitis Prevention and Control as vice president.
Dr.Jia is mainly engaged in the research on the mechanism and intervention of chronic liver disease and liver fibrosis and cirrhosis. He has made some achievements in the fields of the effect of HBV on the proliferation and ECM expression of hepatic stellate cells, the non-invasive diagnosis of liver fibrosis, the management of liver cirrhosis complications, and the clinical research of new drugs for chronic viral hepatitis.
Lilach O. Lerman, M.D., Ph.D., at Mayo Medical College, directs the Renovascular Disease Research Laboratory, which focuses on the development and application of techniques to study renal and cardiovascular physiology and pathophysiology in animal models and in humans.
Dr. Lilach O. Lerman focuses on renovascular disease, cardiorenal interactions, and the kidney and myocardial microcirculation. Her team is engaged in short-term and long-term studies to establish mechanisms of renal and cardiac injury and adaptation to cardiovascular risk factors; the metabolic syndrome; obesity; and atherosclerosis, including vascular remodeling, inflammation, oxidative stress and fibrosis.
Dr. Lerman's research has been funded by the National Institutes of Health and American Heart Association, among other organizations.
Stefano Romeo is Professor in Molecular and Clinical Medicine at the Institute of Medicine at the Sahlgrenska Academy. He has been Director of the Lipid Clinic at the Department of Cardiology and Senior Consultant in Endocrinology at the Sahlgrenska University Hospital. He is also a Faculty Member of the Unit of Human Nutrition at the Department of Medical and Surgical Science, University Magna Graecia, Catanzaro, Italy.
Dr. Romeo's research focus is the role of genetic variants in metabolic disorders such as fatty liver disease (FLD) and cardiovascular disease (CVD). His research field ranges from genetic association studies in large cohorts to molecular genetics and characterization of human mutations.
Amir Lerman, M.D., currently serves as an Associate Chair of the Department of Cardiovascular Medicine and the Director of the Cardiovascular Research Center at Mayo Clinic, a Consultant in the Department of Cardiovascular Medicine at the Mayo Clinic Graduate School of Medicine, and the Medical Director of the Chest Pain and Coronary Physiology Clinic. As an endowed named Barbara Lips Professor of Medicine , he also serves as the Medical Director of Mayo-Israeli startup company initiative and on the faculty of the Merage Institute for Medical Innovation.
Dr. Leman's interest is coronary physiology and imaging, regenerative medicine, innovative technologies, and digital health. Dr. Lerman has published more than 630 manuscripts, book chapters, and reviews. The NIH, AHA, and several foundations support his research.
Stephane Heymans is Professor of Cardiomyopathies and Head of the Centre for Heart Failure Research, Department of Cardiology, Maastricht University, Professor of 'Inflammation and Matrix Biology in Cardiomyopathies' at the University of Leuven.
Dr. Heymans's research focuses on genetic and molecular (inflammatory, fibrotic & metabolic) mechanisms in non-ischemic cardiomyopathies (including HFPEF, myocarditis and dilated cardiomyopathies). He is also the chair of European committees and working groups in the field of myocarditis and cardiomyopathies.
Dr. Jan Borén is Professor and Head of the Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, and physician at the Department of Clinical Chemistry at the Sahlgrenska University Hospital. Dr. Borén also is a member of the Royal Society of Arts and Sciences in Gothenburg, and has awarded numerous honours, including the G?ran Gustafsson's Prize in Medicine from the Royal Academy of Sciences, Dr. Eric K Fernstr?m Foundation's Research Award, and Irvine H. Page Atherosclerosis Research Award. He serves as Vice-President of the European Atherosclerosis Society (EAS), and is Editorial Board Member for Arteriosclerosis, Thrombosis, and Vascular Biology, Section editor for BBA – Molecular and Cell Biology of Lipids and co-Editor of Atherosclerosis.
Dr. Borén’s main long-term interest is in lipid metabolism and he has focused on understanding the underlying mechanisms leading to and consequences of lipid accumulation in the liver, arterial wall and heart, with the aim of translating this knowledge into effective treatment. His research programme is translational and involves both in vitro and in vivo studies, including pathophysiological studies and mouse models, as well as kinetic studies in carefully phenotyped human volunteers.
